"As someone who has been in the business of fighting TB for a long time, I can’t tell you how pleased I am to be able to offer a 3-month regimen: 12 doses and you are done," Dr. Castro said in a telebriefing May 16. Practitioners are always struggling to get patients to complete a 9-month regimen for TB, but with limited success, he said.
"This provides a fantastic opportunity to have the desired impact as a preventive therapy regimen [for TB]," Dr. Castro said.
Dr. Sterling reported that he had no relevant conflicts of interest. Sanofi-Aventis, manufacturer of rifapentine, provided the drug for the trial. Dr. Castro also had no relevant conflicts of interest.